<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373650">
  <stage>Registered</stage>
  <submitdate>14/09/2017</submitdate>
  <approvaldate>21/09/2017</approvaldate>
  <actrnumber>ACTRN12617001341314p</actrnumber>
  <trial_identification>
    <studytitle>Tramadol/Paracetamol (Zaldiar) compared with oxycodone and paracetamol for the management of post-operative pain following major surgery in gynaecology oncology patients</studytitle>
    <scientifictitle>Tramadol/Paracetamol (Zaldiar) compared with oxycodone and paracetamol for the management of post-operative pain following major surgery in gynaecology oncology: comparison of post-operative nausea and constipation</scientifictitle>
    <utrn>U1111-1202-1630 </utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-operative pain</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (cervix)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>	Group A (intervention group)
Patients randomised to group A will have the following post-operative oral medication, once they are deemed suitable for discharge oral analgesia by the treating team:
o	Tramadol/paracetamol orally 37.5 mg/325 mg, two tablets 4 times per day (to continue for one week on discharge)

Patients will be asked on day 7 post discharge how many tablets they have not used in that period

</interventions>
    <comparator>	Group B (usual care group)
Patients randomised to group B will have the following post-operative oral medication, once they are deemed suitable for discharge oral analgesia by the treating team:
o	Paracetamol orally 500mg, two tablets 4 times per day (to continue for one week on discharge)
o	Oxycodone orally 5mg, one - two tablets as needed (maximum 4 times per day) (to continue for one week on discharge)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>	To compare the rates of post-operative nausea in the two groups

As per the validated International Pain Outcomes questionnaire the following is asked on day 7 and 14 post discharge:
Have you had any of the following side effects (nausea, vomiting, drowsiness, constipation) since your discharge from hospital? Please circle "0" if no; if yes, circle the one number that best shows the severity of each (on a scale of 0-10)</outcome>
      <timepoint>7 days post discharge (primary endpoint) and 14 days post discharge</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>	To compare the rates of post-operative constipation in the two groups

As per the validated International Pain Outcomes questionnaire the following is asked on day 7 and 14 post discharge:
Have you had any of the following side effects (nausea, vomiting, drowsiness, constipation) since your discharge from hospital? Please circle "0" if no; if yes, circle the one number that best shows the severity of each (on a scale of 0-10)</outcome>
      <timepoint>7 days post discharge (primary endpoint) and 14 days post discharge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>	To record the rate of any adverse event in each group

As per the validated International Pain Outcomes questionnaire the following is asked on day 7 and 14 post discharge:
Have you had any of the following side effects (nausea, vomiting, drowsiness, constipation) since your discharge from hospital? Please circle "0" if no; if yes, circle the one number that best shows the severity of each (on a scale of 0-10). Other adverse events asked about in the questionnaire are 

For each option below, please choose the number that best describes how much ("0" being
never and "10" being all of the time), since your discharge from hospital, pain interfered with
or prevented you from

4a doing activities in bed such as turning, sitting up, changing position
4b breathing deeply or coughing
4c sleeping


Pain can affect our mood and emotions.
For each option below, please choose the number that best shows how much, since your
discharge from hospital, pain caused you to feel. ("0" being never and "10" being all of the
time)

5a Anxious
5b Helpless

Need to seek additional pain relief

Paracetamol (all adverse events are uncommon)
Dermatologic: Skin rash
Endocrine &amp; metabolic: Decreased serum bicarbonate, decreased serum calcium, decreased serum sodium, hyperchloremia, hyperuricemia, increased serum glucose
Genitourinary: Nephrotoxicity (with chronic overdose)
Hematologic &amp; oncologic: Anemia, leukopenia, neutropenia, pancytopenia
Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin
Hypersensitivity: Hypersensitivity reaction (rare)
Renal: Hyperammonemia, renal disease (analgesic)

Oxycodone
Central nervous system: Drowsiness (23%), headache, dizziness (9% to 13%)
Dermatologic: Pruritus (6% to 13%)
Gastrointestinal: Nausea (15% to 23%), constipation (adults 23%), vomiting (12% to 21%)
Miscellaneous: Fever (1% to 11%)
 

Tramadol
Cardiovascular: Flushing (8% to 16%)
Central nervous system: Dizziness (10% to 33%), headache (4% to 32%), drowsiness (7% to 25%), central nervous system stimulation (7% to 14%), insomnia (2% to 11%)
Dermatologic: Pruritus (3% to 12%)
Gastrointestinal: Constipation (9% to 46%), nausea (15% to 40%), vomiting (5% to 17%), xerostomia (3% to 13%), dyspepsia (1% to 13%)
Neuromuscular &amp; skeletal: Weakness (4% to 12%)
</outcome>
      <timepoint>7 and 14 days post discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>	To determine the rate of readmission 

Patients are followed up by our unit with a clinical review 2-6 weeks post op, where they will be asked if they have been admitted to any other unit in the post-operative period. Patients however are discharged with our contact details and readmissions come back to our unit and under the care of our team and so we are aware of them when this happens.</outcome>
      <timepoint>7 and 28 days post-operatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>	To determine the rate of perceived inadequate pain relief in each group

As per the validated International Pain Outcomes questionnaire the following is asked on day 7 and 14 post discharge:

Since your discharge, how well controlled do you feel
your pain has been?
Please choose the percentage (0-100%) that best shows
how much relief you have received from all of your
pain treatments.

</outcome>
      <timepoint>7 and 14 days post discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>	To determine the need to additional pain relief in each group

As per the validated International Pain Outcomes questionnaire the following is asked on day 7 and 14 post discharge:

Since discharge, have you sought additional pain relief other than what you were sent home
with from any of the following

8a Emergency department
8b General practitioner
8c Pharmacist
8d Other

9 Would you have liked to be discharged with more pain treatment that you received?</outcome>
      <timepoint>7 and 14 days post discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>	Patients planned for major surgery for both benign and malignant in the department of gynaecological oncology will be approached for recruitment into the study.
	Aged 18 or over
	English speaking
	Willingness to give written informed consent, and willingness to participate to and comply with the study.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>	Non-English speaking or unable to provide informed consent 
	Patients with a documented allergy or contraindication to any of the drugs included in group A or B 
	Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study. 
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is concealed by central randomisation by the gynaecology patient management system</concealment>
    <sequence>Randomisation will take place via a dedicated module to the gynaecology patient management system in a 1:1 ratio (intervention: control).</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Based on an assumed rate of 40% nausea associated with oxycodone and a rate of 20% associated with tramadol, we calculate that a sample size of 79 in each group is needed to detect a 50% reduction in nausea with a power of 80%. Allowing for a 15% attrition rate, we aim to recruit 93 participants in each group. 

Analysis
Analysis will be as intention to treat. Data will be summarised using means and standard deviations or medians, interquartile ranges and ranges for continuous data and frequency distributions for categorical data. Univariate comparisons will be made using independent t-tests for continuous outcomes and Chi-square or Fisher exact tests for categorical comparisons. We plan to conduct a multivariable logistic regression analysis for the nominal primary outcomes, adjusting for the variables below. All tests will be two-sided and a p-value &lt;0.05 will be considered statistically significant for the overall analysis.  

Variables
The following factors will be adjusted for
-	Age (&lt;65 compared with 65 or older)
-	Mode of surgery (open or laparoscopic)
-	Use of TAP blocks in the peri-operative period
-	Use of PCA in the post-operative period
-	Amount of opioid use prior to discharge
-	Malignant or benign pathology
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/07/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>186</samplesize>
    <actualsamplesize />
    <currentsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>28/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>The Chris Oâ€™Brien Lifehouse - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Chris O'Brien Lifehouse</primarysponsorname>
    <primarysponsoraddress>119-143 Missenden Rd, Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Chris O'Brien Lifehouse</fundingname>
      <fundingaddress>119-143 Missenden Rd, Camperdown NSW 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to investigate the efficacy and safety of tramadol/paracetamol combined dosing compared with paracetamol and oxycodone for pain management following major surgery in gynaecology oncology patients. 

Who is it for?
You may be eligible to join this study if you are a female aged 18 years or more who is planned for major surgery for either benign or malignant tumours in gynaecological oncology.

Study details
Participants in this study will be randomly allocated (by chance) to one of two groups. Participants in one group will take oral Tramadol/paracetamol for post-operative pain management in the week following hospital discharge. Participants in the other group will take oral paracetamol and oxycodone in the week following discharge.

All participants will be followed-up for 28 days in order to evaluate post-operative nausea, constipation, adverse events, hospital re-admission rates, and efficacy of pain relief. We hope to determine whether Tramadol / paracetamol is a safe, effective, and well-tolerated option for post-operative pain management.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Submitted, not yet approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Local Health District Ethics Review Committee</ethicname>
      <ethicaddress> 575 Canterbury Rd, Campsie NSW 2194, Australia</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>14/09/2017</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Sam Saidi</name>
      <address>Chris O'Brien Lifehouse
119-143 Missenden Rd, Camperdown NSW 2050</address>
      <phone>+61285140258</phone>
      <fax />
      <email>sam.saidi@lh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Emma Allanson</name>
      <address>Chris O'Brien Lifehouse
119-143 Missenden Rd, Camperdown NSW 2050</address>
      <phone>+61285140730</phone>
      <fax />
      <email>emma.allanson@lh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Emma Allanson</name>
      <address>Chris O'Brien Lifehouse
119-143 Missenden Rd, Camperdown NSW 2050</address>
      <phone>+61285140730</phone>
      <fax />
      <email>emma.allanson@lh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Emma Allanson</name>
      <address>Chris O'Brien Lifehouse
119-143 Missenden Rd, Camperdown NSW 2050</address>
      <phone>+61285140730</phone>
      <fax />
      <email>emma.allanson@lh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>